×
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
NASDAQ:ABUS

Arbutus Biopharma (ABUS) Stock Forecast, Price & News

$2.48
+0.17 (+7.36%)
(As of 05/27/2022 04:00 PM ET)
Add
Compare
Today's Range
$2.27
$2.50
50-Day Range
$1.98
$3.17
52-Week Range
$1.93
$6.50
Volume
1.08 million shs
Average Volume
2.08 million shs
Market Capitalization
$368.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.66
30 days | 90 days | 365 days | Advanced Chart
Receive ABUS News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Arbutus Biopharma logo

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABUS
Employees
85
Year Founded
1992

Sales & Book Value

Annual Sales
$10.99 million
Book Value
$1.12 per share

Profitability

Net Income
$-76.25 million
Net Margins
-352.49%
Pretax Margin
-331.78%

Debt

Price-To-Earnings

Miscellaneous

Free Float
140,994,000
Market Cap
$368.85 million
Optionable
Optionable

Company Calendar

Last Earnings
5/05/2022
Today
5/27/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

1.63 out of 5 stars

Medical Sector

960th out of 1,424 stocks

Pharmaceutical Preparations Industry

481st out of 681 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions

Is Arbutus Biopharma a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Arbutus Biopharma stock.
View analyst ratings for Arbutus Biopharma
or view top-rated stocks.

When is Arbutus Biopharma's next earnings date?

Arbutus Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Arbutus Biopharma
.

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Co. (NASDAQ:ABUS) announced its quarterly earnings data on Thursday, May, 5th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.02. The biopharmaceutical company earned $12.58 million during the quarter, compared to analysts' expectations of $5.77 million. Arbutus Biopharma had a negative net margin of 352.49% and a negative trailing twelve-month return on equity of 121.30%. During the same period last year, the firm posted ($0.21) EPS.
View Arbutus Biopharma's earnings history
.

What price target have analysts set for ABUS?

4 analysts have issued twelve-month price objectives for Arbutus Biopharma's stock. Their forecasts range from $5.00 to $9.00. On average, they anticipate Arbutus Biopharma's share price to reach $7.13 in the next twelve months. This suggests a possible upside of 187.3% from the stock's current price.
View analysts' price targets for Arbutus Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Arbutus Biopharma's key executives?
Arbutus Biopharma's management team includes the following people:
  • Mr. William H. Collier, Pres, CEO & Director (Age 61, Pay $1.03M)
  • Mr. David C. Hastings CPA, CFO & Chief Accounting Officer (Age 61, Pay $647.1k)
  • Dr. Michael J. Sofia Ph.D., Chief Scientific Officer (Age 64, Pay $670.22k)
  • Pam Murphy, Investor Relations Consultant
  • Ms. Lisa M. Caperelli, VP of Investor Relations
  • Dr. Elizabeth Howard, Exec. VP, Gen. Counsel, Chief Compliance Officer & Sec. (Age 68)
  • Dr. Gaston Picchio Ph.D., Chief Devel. Officer (Age 58)
  • Mr. Michael J. McElhaugh, Chief Bus. Officer (Age 47)
  • Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C, Q.C., Sec. (Age 71)
What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO?

6 employees have rated Arbutus Biopharma CEO Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among Arbutus Biopharma's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arbutus Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.59%), Vanguard Group Inc. (3.19%), Two Seas Capital LP (1.48%), Assenagon Asset Management S.A. (1.43%), State Street Corp (1.19%) and Goldman Sachs Group Inc. (1.04%).
View institutional ownership trends for Arbutus Biopharma
.

Which institutional investors are selling Arbutus Biopharma stock?

ABUS stock was sold by a variety of institutional investors in the last quarter, including Group One Trading L.P., Jacob Asset Management of New York LLC, PEAK6 Investments LLC, Jane Street Group LLC, HAP Trading LLC, Simplex Trading LLC, Cutler Group LP, and XTX Topco Ltd.
View insider buying and selling activity for Arbutus Biopharma
or view top insider-selling stocks.

Which institutional investors are buying Arbutus Biopharma stock?

ABUS stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Two Seas Capital LP, Goldman Sachs Group Inc., BlackRock Inc., Wellington Management Group LLP, Vanguard Group Inc., State Street Corp, and Bank of Montreal Can.
View insider buying and selling activity for Arbutus Biopharma
or or view top insider-buying stocks.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $2.48.

How much money does Arbutus Biopharma make?

Arbutus Biopharma has a market capitalization of $368.85 million and generates $10.99 million in revenue each year. The biopharmaceutical company earns $-76.25 million in net income (profit) each year or ($0.730010) on an earnings per share basis.

How many employees does Arbutus Biopharma have?

Arbutus Biopharma employs 85 workers across the globe.

When was Arbutus Biopharma founded?

Arbutus Biopharma was founded in 1992.

What is Arbutus Biopharma's official website?

The official website for Arbutus Biopharma is www.arbutusbio.com.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The biopharmaceutical company can be reached via phone at (267) 469-0914, via email at [email protected], or via fax at 604-419-3201.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.